---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-040625"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:58:52.995831+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics presents positive MT1-MMP imaging data from 12 solid tumor patients at AACR 2025

## Summary
- Data from 12 patients validate MT1-MMP as cancer target; BRC tracer showed uptake in primary tumors and metastases.
- In lung cancer patient, MT1-MMP-PET showed BRC uptake in primary tumor (SUVmax 6.0) and bone metastases (SUVmax 7.9).
- In breast/bladder cancer patient, MT1-MMP-PET revealed higher uptake than CT; IHC confirmed MT1-MMP expression in tumor.
- Second BRC molecule targeting EphA2: initial human imaging data expected 2H 2025; company-sponsored trials planned for 2026.
- Overall, 12 of 14 patients imaged successfully; results support radiopharmaceutical therapy potential.

## SEC filing metadata
- accession: 0001104659-25-040625
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465925040625/0001104659-25-040625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465925040625/tm2513386d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-040625
- JSON: https://secwatch.observer/filing/0001104659-25-040625.json
- Plain text: https://secwatch.observer/filing/0001104659-25-040625.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.